Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
37.5(c) 36.27(c) 36.61(c) 38.4(c) 39.75(c) Last
366 551 501 271 664 689 616 024 1 930 579 Volume
-1.60% -3.28% +0.94% +4.89% +3.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 154 M - -
Net income 2021 -215 M - -
Net cash position 2021 362 M - -
P/E ratio 2021 -26,4x
Yield 2021 -
Sales 2022 209 M - -
Net income 2022 -245 M - -
Net cash position 2022 207 M - -
P/E ratio 2022 -23,2x
Yield 2022 -
Capitalization 5 595 M 5 595 M -
EV / Sales 2021 34,0x
EV / Sales 2022 25,8x
Nbr of Employees 622
Free-Float 98,4%
More Financials
Company
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. 
More about the company
Ratings of Adaptive Biotechnologies Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
09/16ADAPTIVE BIOTECHNOLOGIES : to Present New SARS-CoV-2 Data from its Immune Medici..
AQ
09/16Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medic..
CI
09/13INSIDER SELL : Adaptive Biotechnologies
MT
09/07ADAPTIVE BIOTECHNOLOGIES : to Present at the Morgan Stanley Global Healthcare Co..
AQ
08/10CUREBASE : Adaptive Biotechnologies Announce Collaboration to Expand Clinical St..
PR
08/10Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical ..
CI
08/06ADAPTIVE BIOTECHNOLOGIES : Goldman Sachs Adjusts Price Target on Adaptive Biotec..
MT
08/05ADAPTIVE BIOTECHNOLOGIES : Appoints Chief Commercial Officer
MT
08/04ADAPTIVE BIOTECHNOLOGIES : Reports Second Quarter 2021 Financial Results (Form 8..
PU
08/04ADAPTIVE BIOTECHNOLOGIES : Q2 Earnings Snapshot
AQ
08/04ADAPTIVE BIOTECHNOLOGIES : Management's Discussion and Analysis of Financial Con..
AQ
08/04ADAPTIVE BIOTECHNOLOGIES : Second Quarter Earnings Presentation
PU
08/04ADAPTIVE BIOTECHNOLOGIES CORP : Results of Operations and Financial Condition, F..
AQ
08/04ADAPTIVE BIOTECHNOLOGIES : Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Report..
MT
08/04Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
GL
More news
News in other languages on ADAPTIVE BIOTECHNOLOGIES CORPORATION

- No features available -

More news
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
More recommendations
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | ADPT | US00650F1093 | MarketScreener
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 39,75 $
Average target price 56,67 $
Spread / Average Target 42,6%
EPS Revisions
Managers and Directors
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Chad M. Cohen Chief Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Lance Baldo Chief Medical Officer
Sector and Competitors